(TA-luh-ZOH-puh-rib TOH-suh-layt)
This page contains brief information about talazoparib tosylate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Talazoparib tosylate is approved to treat:
- Breast cancer that is HER2 negative and has certain germline mutations in the BRCA1 or BRCA2 gene. It is used alone in adults whose cancer has spread to nearby tissues.
- Prostate cancer that has certain mutations in genes involved in the HRR pathway. It is used with enzalutamide in adults whose cancer has spread to other parts of the body and is castrate resistant (has not responded to treatments that lower testosterone levels).
Talazoparib tosylate is also being studied in the treatment of other types of cancer.
More About Talazoparib Tosylate
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Talazoparib Tosylate – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
FDA Approves New Initial Treatment Option for Some Metastatic Prostate Cancers
Can an Antibiotic Treat Cancers that Become Resistant to PARP Inhibitors?
Clinical Trials Accepting Patients
Find Clinical Trials for Talazoparib Tosylate – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
